A high court judge in England has rejected an application for a judicial review of the way that the health technology appraisal body NICE approached its evaluation of BioMarin’s Kuvan (sapropterin) for the rare metabolic disease phenylketonuria (PKU).
The decision has disappointed critics of NICE’s approach to rare disease treatments, including BioMarin, but the institute said the decision...








